GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Total Stockholders Equity

Axogen (Axogen) Total Stockholders Equity : $95.7 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Axogen Total Stockholders Equity?

Axogen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $95.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Axogen's Book Value per Share for the quarter that ended in Dec. 2023 was $2.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Axogen's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.72.

Axogen Total Stockholders Equity Historical Data

The historical data trend for Axogen's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Total Stockholders Equity Chart

Axogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.15 123.15 112.55 101.00 95.67

Axogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.00 97.51 97.15 97.81 95.67

Axogen  (NAS:AXGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Axogen's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(95.665-0)/43.1245
=2.22

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Axogen's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.547 + 67.745) / 95.665
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axogen Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Axogen's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Axogen (Axogen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Total Stockholders Equity
Comparable Companies
LUNG TLSI CERS CVRX SGHT VMD BVS TCMD SENS RCEL ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN
Traded in Other Exchanges
LT3:Germany
Address
13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Website
https://www.axogeninc.com
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Executives
Peter J Mariani officer: Chief Financial Officer C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr. director HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Marc A Began officer: EVP & General Counsel C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall director 13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Karen L. Zaderej director, officer: CEO AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Michael Patrick Donovan officer: VP Operations C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Maria D. Martinez officer: Chief Human Resources Officer C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Alan M Levine director C/O AXOGEN, INC., 13631 PROGRESS BLVD. - SUITE 400, ALACHUA FL 32615
Mark Stephen Gold director 13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Quentin S. Blackford director 7475 LUSK BLVD., SAN DIEGO CA 92121